DESLORATADINE; PSEUDOEPHEDRINE SULFATE - Generic Drug Details

What are the generic sources for desloratadine; pseudoephedrine sulfate and what is the scope of freedom to operate?

Desloratadine; pseudoephedrine sulfate is the generic ingredient in three branded drugs marketed by Organon, Organon Llc, and Dr Reddys Labs Ltd, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for DESLORATADINE; PSEUDOEPHEDRINE SULFATE

US Patents:	0
Tradenames:	3
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
DailyMed Link:	DESLORATADINE; PSEUDOEPHEDRINE SULFATE at DailyMed

Recent Clinical Trials for DESLORATADINE; PSEUDOEPHEDRINE SULFATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dr. Reddy's Laboratories Limited	Phase 1

See all DESLORATADINE; PSEUDOEPHEDRINE SULFATE clinical trials

Pharmacology for DESLORATADINE; PSEUDOEPHEDRINE SULFATE

Drug Class	Histamine-1 Receptor Antagonist alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Histamine H1 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for DESLORATADINE; PSEUDOEPHEDRINE SULFATE

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

R01AA	Sympathomimetics, plain
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01AB	Sympathomimetics, combinations excl. corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01BA	Sympathomimetics
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03CA	Alpha- and beta-adrenoreceptor agonists
R03C	ADRENERGICS FOR SYSTEMIC USE
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R06AX	Other antihistamines for systemic use
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

R06AX	Other antihistamines for systemic use
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

S01FB	Sympathomimetics excl. antiglaucoma preparations
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for DESLORATADINE; PSEUDOEPHEDRINE SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	CLARINEX D 24 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021605-001	Mar 3, 2005		DISCN	Yes	No
Organon Llc	CLARINEX-D 12 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021313-001	Feb 1, 2006		RX	Yes	Yes
Dr Reddys Labs Ltd	DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	078366-001	Apr 26, 2011		RX	No	Yes

Expired US Patents for DESLORATADINE; PSEUDOEPHEDRINE SULFATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Llc	CLARINEX-D 12 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021313-001	Feb 1, 2006
Organon	CLARINEX D 24 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021605-001	Mar 3, 2005
Organon Llc	CLARINEX-D 12 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021313-001	Feb 1, 2006
Organon Llc	CLARINEX-D 12 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021313-001	Feb 1, 2006
Organon	CLARINEX D 24 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021605-001	Mar 3, 2005
Organon Llc	CLARINEX-D 12 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021313-001	Feb 1, 2006

Market and Financial Outlook for Desloratadine and Pseudoephedrine Sulfate

Last updated: February 13, 2026

---

What Are the Market Sizes and Growth Trends for Desloratadine and Pseudoephedrine Sulfate?

Desloratadine, an antihistamine marketed primarily under brand names like Clarinex, addresses allergic rhinitis and chronic idiopathic urticaria. The pseudoephedrine sulfate, a decongestant often combined with antihistamines, appears in numerous OTC and prescription formulations.

The global allergy medication market was valued at approximately USD 11 billion in 2022, with an expected compound annual growth rate (CAGR) of around 6% from 2023 to 2030 [1].

Pseudoephedrine sulfate remains a staple in decongestant formulations, dominated by OTC sales globally. The decongestant segment within cold and allergy remedies is projected to reach USD 8 billion by 2026, growing at about 4% annually [2].

---

How Do Patent Statuses and Regulatory Approvals Affect Market Access?

Desloratadine

• Patented until 2023 (patent expiration date varies by country).
• Post-patent, multiple generic versions entered the market.
• Regulatory approvals in over 100 countries, with the FDA approving Clarinex in 2001.

Pseudoephedrine Sulfate

• Comprises generics solely; no recent patents.
• Regulatory constraints imposed to limit misuse due to its role in illicit methamphetamine production.
• Governed under regulations such as the US Combat Methamphetamine Epidemic Act (2005), limiting sales quantities and requiring ID checks.

Impact

Patent expiration has increased generic competition for desloratadine, leading to price reductions and market share shifts. Pseudoephedrine's regulation reduces competitive disparities but limits new formulations.

---

What Are the Key Drivers and Challenges in Market Growth?

Drivers

• Increased prevalence of allergic rhinitis and sinus congestion.
• Growth in aging populations with more allergy and cold-related ailments.
• Rising consumer preference for OTC medications, facilitating broad distribution.

Challenges

• Strict regulations around pseudoephedrine reduce availability and consumer access.
• Generic price reductions compress margins for manufacturers.
• Regulatory bottlenecks for new formulations or combination therapies.

---

What Are the Expected Revenue Trends and Profitability Prospects?

Desloratadine

• Peak global sales surpassed USD 2.5 billion in 2019, with subsequent stagnation due to generic entry.
• Revenue declines expected in the next 2-3 years due to patent expiry.
• Revenue recovery hinges on the introduction of new formulations, biosimilars, or combination drugs.

Pseudoephedrine Sulfate

• Solid OTC sales with steady revenue flow.
• Margins remain tight due to generic competition.
• Regulatory restrictions limit innovation but support stable demand.

Profitability

• Desloratadine's profitability diminished post-patent expiry; companies focused on cost efficiency.
• Pseudoephedrine profit margins are thin but maintain stable due to high volume.

---

What Are the Implications of Regulatory and Market Trends for Stakeholders?

Pharmaceutical Manufacturers

• Need for pipelines of new antihistamines or combination drugs to offset patent cliffs.
• Strategic focus on biosimilars and novel delivery systems.

Investors

• Risk of revenue erosion post-patent expiry.
• Opportunities in markets with unmet needs or emerging markets.

Regulators

• Tightening controls on pseudoephedrine complicate supply chains.
• Push towards developing abuse-deterrent formulations.

---

Final Assessment

The outlook for desloratadine is characterized by patent expiry-driven revenue decline, with potential recovery through new product launches. Pseudoephedrine sulfate maintains steady OTC sales but faces regulatory headwinds that limit growth.

The overall market remains attractive, buoyed by rising allergy and cold-related disease burdens. However, price pressures from generics and regulatory constraints present ongoing challenges.

---

Key Takeaways

• Desloratadine's global sales peaked pre-2020, with revenues declining due to patent expiration.
• Generics dominate the desloratadine market; innovation shifts towards combination drugs.
• Pseudoephedrine sales remain stable, but regulatory restrictions limit supply and innovation.
• Market growth depends on addressing unmet needs and navigating regulatory environments.
• Stakeholders must adapt through product innovation, cost management, and regulatory compliance.

---

FAQs

1. Will desloratadine regain market share via new formulations?
Potential exists if new delivery forms (e.g., extended-release or combination products) gain regulatory approval and consumer acceptance, but timing remains uncertain.

2. How does regulation impact pseudoephedrine sales?
Regulations restrict OTC quantities and impose record-keeping, reducing ease of access but controlling misuse. Impact varies by jurisdiction.

3. Are biosimilars affecting the antihistamine market?
Not directly, as biosimilars pertain to biologics. However, biosimilar development trends influence pharmaceutical R&D focus.

4. What impact do patent expirations have on pricing?
Patents' expiration leads to price reductions due to increased generic competition, eroding profit margins.

5. Are innovative delivery mechanisms emerging for these drugs?
Research explores combination therapies and alternative delivery routes, but widespread adoption remains limited.

---

Sources

1. MarketWatch. (2022). Allergy Medication Market Size, Share & Trends Analysis.
2. GlobalData. (2023). Cold & Allergy Drugs Forecast.